A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Paul F. Robbins; Sadik H. Kassim; Thai L.N. Tran; Jessica S. Crystal; Richard A. Morgan; Steven A. Feldman; James Chih‐Hsin Yang; Mark E. Dudley; John R. Wunderlich; Richard M. Sherry; Udai S. Kammula; Marybeth S. Hughes; Nicholas P. Restifo; Mark Raffeld; Chyi‐Chia Richard Lee; Yong F. Li; Mona El‐Gamil; Steven A. Rosenberg

doi:10.1158/1078-0432.ccr-14-2708

Abstract

The adoptive transfer of autologous T cells transduced with a retrovirus encoding a TCR against an HLA-A*0201 restricted NY-ESO-1 epitope can be an effective therapy for some patients bearing synovial cell sarcomas and melanomas that are refractory to other treatments.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Robbins et al. (2014) studied this question.

synapsesocial.com/papers/69d9cfbd0f32475823a3c667 https://doi.org/10.1158/1078-0432.ccr-14-2708

View Full Paper

Ask AI

Bookmark

Share

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Abstract

Discussion

Cite This Study

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Clinical Cancer Research

Keep reading

More related papers

More from Clinical Cancer Research